Free Trial

Relay Therapeutics (RLAY) Stock Price, News & Analysis

Relay Therapeutics logo
$5.11 -0.49 (-8.76%)
(As of 11/15/2024 ET)

About Relay Therapeutics Stock (NASDAQ:RLAY)

Key Stats

Today's Range
$5.03
$5.63
50-Day Range
$5.11
$9.51
52-Week Range
$5.03
$12.14
Volume
1.93 million shs
Average Volume
1.25 million shs
Market Capitalization
$854.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.22
Consensus Rating
Moderate Buy

Company Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
63rd Percentile Overall Score

RLAY MarketRank™: 

Relay Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 350th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Relay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Relay Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Relay Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Relay Therapeutics are expected to decrease in the coming year, from ($2.61) to ($2.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Relay Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Relay Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Relay Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Relay Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.19% of the outstanding shares of Relay Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Relay Therapeutics has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Relay Therapeutics has recently increased by 1.52%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Relay Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Relay Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.19% of the outstanding shares of Relay Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Relay Therapeutics has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in Relay Therapeutics has recently increased by 1.52%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Relay Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Relay Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $51,043.00 in company stock.

  • Percentage Held by Insiders

    Only 4.32% of the stock of Relay Therapeutics is held by insiders.

  • Percentage Held by Institutions

    96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Relay Therapeutics' insider trading history.
Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RLAY Stock News Headlines

FY2024 Earnings Forecast for RLAY Issued By Leerink Partnrs
[Urgent] Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
TD Cowen Keeps Their Buy Rating on Relay Therapeutics (RLAY)
See More Headlines

RLAY Stock Analysis - Frequently Asked Questions

Relay Therapeutics' stock was trading at $11.01 at the beginning of the year. Since then, RLAY stock has decreased by 53.6% and is now trading at $5.1050.
View the best growth stocks for 2024 here
.

Relay Therapeutics, Inc. (NASDAQ:RLAY) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $0.14. The firm's revenue for the quarter was down 100.0% on a year-over-year basis.

Relay Therapeutics (RLAY) raised $250 million in an IPO on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Relay Therapeutics' top institutional investors include Bellevue Group AG (5.51%), State Street Corp (3.21%), Braidwell LP (2.61%) and Geode Capital Management LLC (2.04%). Insiders that own company stock include Mark Murcko, Sanjiv Patel, Donald A Bergstrom, Peter Rahmer, Thomas Catinazzo, Brian Adams and Andy Porter.
View institutional ownership trends
.

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Novo Nordisk A/S (NVO), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/06/2024
Today
11/17/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/27/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RLAY
Fax
N/A
Employees
304
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.22
High Stock Price Target
$28.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+315.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-341,970,000.00
Pretax Margin
-3,449.57%

Debt

Sales & Book Value

Annual Sales
$25.55 million
Book Value
$6.27 per share

Miscellaneous

Free Float
128,106,000
Market Cap
$683.51 million
Optionable
Optionable
Beta
1.67
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:RLAY) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners